Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
		Sep. 29, 2018		Sep. 30, 2017	Sep. 29, 2018		Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Net sales		$ 1,133.1	[1]	$ 1,231.3	$ 3,536.5	[1]	$ 3,663.1
CHCA
Disaggregation of Revenue [Line Items]
Net sales		596.2		598.8	1,794.6		1,786.4
CHCA | Cough/Cold/Allergy/Sinus
Disaggregation of Revenue [Line Items]
Net sales	[2]	113.8			364.6
CHCA | Infant Nutritionals
Disaggregation of Revenue [Line Items]
Net sales	[2]	112.4			325.0
CHCA | Analgesics
Disaggregation of Revenue [Line Items]
Net sales	[2]	96.8			282.7
CHCA | Gastrointestinal
Disaggregation of Revenue [Line Items]
Net sales	[2]	95.4			290.6
CHCA | Smoking Cessation
Disaggregation of Revenue [Line Items]
Net sales	[2]	72.8			209.9
CHCA | Animal Health
Disaggregation of Revenue [Line Items]
Net sales	[2]	20.4			78.6
CHCA | Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales	[2]	5.0			12.3
CHCA | Other CHCA
Disaggregation of Revenue [Line Items]
Net sales	[2],[3]	79.6			230.9
CHCI
Disaggregation of Revenue [Line Items]
Net sales		357.6		365.4	1,140.0		1,116.8
CHCI | Cough, Cold, and Allergy
Disaggregation of Revenue [Line Items]
Net sales		94.8			278.2
CHCI | Lifestyle
Disaggregation of Revenue [Line Items]
Net sales		70.5			246.3
CHCI | Personal Care and Derma-Therapeutics
Disaggregation of Revenue [Line Items]
Net sales		60.0			215.3
CHCI | Anti-Parasite
Disaggregation of Revenue [Line Items]
Net sales		30.2			88.7
CHCI | Natural Health and Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales		32.2			93.3
CHCI | Other CHCI
Disaggregation of Revenue [Line Items]
Net sales	[4]	69.9			218.2
RX
Disaggregation of Revenue [Line Items]
Net sales		$ 179.3		$ 250.6	$ 601.9		$ 708.4

[1] Derived from the location of the entity that sells to a third party.

[2] Includes net sales from our OTC contract manufacturing business.

[3] Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

[4] Consists primarily of liquid licensed products, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.